Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...
TipRanks on MSN
GSK’s new study on belantamab mafodotin: A potential game-changer for multiple myeloma treatment
GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A ...
From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...
MedPage Today on MSN
Novel Pills Promising in Relapsed/Refractory Multiple Myeloma
Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...
Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...
Dr. Amany Keruakous sat down for an interview with CURE, in which she discussed how bispecific antibodies for multiple ...
Other abstracts will offer data on bispecifics moving into frontline therapy; examples include data coming Saturday from EPCORE-NHL2 involving epcoritamab in diffuse large B-cell lymphoma, and the ...
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback